rss
Qual Saf Health Care 15:251-257 doi:10.1136/qshc.2005.016162
  • Original Article

Overprescribing of lipid lowering agents

  1. M A Smith1,
  2. E D Cox2,
  3. J M Bartell3
  1. 1Department of Population Health Sciences, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
  2. 2Department of Population Health Sciences and the Center for Women’s Health Research, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
  3. 3Group Health Cooperative of South Central Wisconsin, Madison, WI, USA
  1. Correspondence to:
 Dr MA Smith
 Associate Professor, Department of Population Health Sciences, University of Wisconsin School of Medicine and Public Health, 505 WARF Bldg, 610 Walnut St, Madison, WI 53726-2397, USA; maureensmith{at}wisc.edu
  • Accepted 2 April 2006

Abstract

Background: Undertreatment of hyperlipidemia has received considerable attention. However, little is known about trends in overprescribing of lipid lowering agents. We examined these trends and their associations with physician, practice, and organisational factors.

Methods: 2034 physicians were surveyed twice: baseline (1996–7) and follow up (1998–9). On each occasion they were asked: “For what percentage of 50 year old men without other cardiac risk factors would you recommend an oral agent for total cholesterol of 240, LDL 150, and HDL 50 after 6 months on a low cholesterol diet?” During the survey period the National Cholesterol Education Program guidelines did not recommend prescribing for these patients. Binomial and multinomial logistic regressions assessed baseline overprescribing and longitudinal changes in overprescribing, accounting for complex sampling.

Results: 39% of physicians recommended prescribing at baseline (round 1), increasing at follow up (round 2) to 51% (p<0.001). Physicians who were more likely to overprescribe at baseline were less likely to be board certified (odds ratio (OR) 0.49, 95% confidence interval (CI) 0.38 to 0.63; p<0.001), were in solo or two-physician practices (OR 1.88, 95% CI 1.46 to 2.41; p<0.001), had more revenue from Medicare (OR 1.10, 95% CI 1.03 to 1.17; p = 0.004) or Medicaid (OR 1.09, 95% CI 1.01 to 1.18; p = 0.03), or were family physicians (OR 1.87, 95% CI 1.35 to 2.58; p<0.001). Physicians with large increases in overprescibing were more likely than those with small increases in overprescribing to be international medical graduates (OR 2.09, 95% CI 1.20 to 3.64; p = 0.011) and to spend more hours in patient care (OR 1.14, 95% CI 1.03 to 1.26; p = 0.016).

Conclusions: Overprescribing of lipid lowering agents is commonplace and increased. At baseline and longitudinally, overprescribing was primarily associated with physician and practice characteristics and not with organisational factors.

Footnotes

  • Dr Cox was funded by AHRQ grant #K08 HS13183. Dr Bartell was funded by NIH grant #T32 AG00265.

  • Competing interests: none.

  • An abstract of the preliminary findings was presented at the AcademyHealth Annual Meeting, June 2004.

No Related Web Pages

Free sample

This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of BMJ Quality & Safety.
View free sample issue >>

Email alerts

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

 

Navigate This Article